u-62840 has been researched along with Sarcoidosis* in 2 studies
2 other study(ies) available for u-62840 and Sarcoidosis
Article | Year |
---|---|
Clinical and molecular study of 4 cases of pulmonary hypertension associated with sarcoidosis.
Sarcoidosis is a pleomorphic disease that can present with pulmonary hypertension (PH). What little information is available about the association of these two diseases comes mainly from small series of patients scheduled for transplant. We present 4 cases of mild pulmonary involvement in whom right catheterisation was performed and PH-specific therapy was administered. After obtaining written consent, a genetic study was performed that showed mutations in PH-related genes in 3 of the patients. This is the first study of its kind to yield genetic information for this type of PH. Topics: Bone Morphogenetic Protein Receptors, Type II; Bosentan; Disease Progression; Epoprostenol; Fatal Outcome; Female; Humans; Hypertension, Pulmonary; Kv1.5 Potassium Channel; Male; Middle Aged; Mutation; Phenylpropionates; Point Mutation; Pyridazines; Respiratory Function Tests; RNA, Messenger; Sarcoidosis; Sildenafil Citrate; Sulfonamides; Tadalafil; Treatment Outcome | 2015 |
Use of pulmonary arterial hypertension-specific therapy in non-WHO group I pulmonary hypertension.
The development of pulmonary hypertension (PH) in non-World Health Organization group I PH adversely affects exercise capacity. It is unclear whether pulmonary artery hypertension (PAH)-specific drugs improve pulmonary hemodynamics and exercise capacity in such patients.. We performed a retrospective chart review of consecutive patients with non-World Health Organization group I PH treated with PAH-specific therapy.. We identified 24 patients. The mean (standard deviation) age was 48 (14.8) years. Seventeen (71%) patients were women. The 6-minute walk distance improved significantly for the whole group in an initial follow-up period of 4.6 (2.3) months; however, the improvement was seen only in patients with obstructive sleep apnea (OSA) or severe PH and it was not sustained during a longer follow-up period of 11.5 (4.1) months, except in patients with OSA. PH was treated with a variety of PAH-specific drugs, including combination therapy in five patients.. The use of PAH-specific therapy in selected patients with PH secondary to lung diseases, OSA, or sarcoidosis may result in significant improvement in 6-minute walk distance, particularly in patients with OSA or severe PH. Topics: Adult; Antihypertensive Agents; Cohort Studies; Endothelin Receptor Antagonists; Epoprostenol; Exercise Test; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostaglandins; Pulmonary Disease, Chronic Obstructive; Respiratory Function Tests; Retrospective Studies; Sarcoidosis; Severity of Illness Index; Sleep Apnea, Obstructive; Treatment Outcome; World Health Organization | 2015 |